"Designing Growth Strategies is in our DNA"
A Biosimilar is a biotherapeutic product that is similar in terms of quality, safety, and efficacy to an already licensed reference biopharmaceutical product, also known as a biologic drug. But, biologic drugs are costlier though effective and are leading to greater costs per patient and a number of patents of biologics are expiring. Biosimilars are used for a number of disorders relating to the immune system, such as various types of arthritis like rheumatoid arthritis, Crohn’s Disease, ankylosing spondylitis, psoriasis, hidradenitis suppurativa, and ulcerative colitis.
The market is expected to grow because the Immunology Biosimilars pipeline shows remarkable and sustained growth. Due to the demand for better therapeutics as compared to generic drugs, the immunology Biosimilars Market is growing, because it is cheaper than the biologics. The Immunology biosimilars market is expected to grow due to the patents of the number of biologics expiring or already expired. Some of them are Rituxan (rituximab), Humira (adalimumab), Enbrel (etanercept) and Remicade (Infliximab).
To gain extensive insights into the market, Request for Customization
The growth in the number of products in the advanced stages of R&D along with a number of recent regulatory approvals are further expected to boost the market. Due to the comparatively lesser cost of the biosimilars compared to the biologics and the effectiveness of the biosimilars compared to the conventional treatment options are further driving the market growth positively.
The factor that is expected to inhibit the growth of the market is the complex manufacturing process of the immunology biosimilars. Another main factor that can limit the growth of the market is the stringent regulatory scenario for immunology biosimilars. Apart from the stringent regulatory scenario, the approvals process for the immunology biosimilars also includes a few additional tests, so that the immunology biosimilars can be termed interchangeable to their biologics counterparts.
Some of the major companies that are present in the global Immunology Biosimilars market are Novartis AG, Pfizer Inc., Mylan N.V., AbbVie Inc., STADA Arzneimittel AG, Celltrion, Inc., KBI Biopharma, Inc., Amgen Inc, and other players.
· Inflammatory Bowel Disease
· Hospital Pharmacies
· Retail Pharmacies
· Online Pharmacies
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
At present, inflammatory bowel disease and arthritis account for the largest proportion of the market and this due to the increased demand for biosimilars as the cost-effective treatment option for these diseases.
The global immunology biosimilars market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are the two largest markets for immunology biosimilars at present and they are expected to account for a large proportion of the market in the forecast period as well. This is because due to the increasing approvals of immunology biosimilars in the region due to the extensive research & development and the ongoing approvals for the immunology biosimilars. In the Asia Pacific region, Japan is expected to provide the largest market opportunity. This because of the increasing adoption of biosimilars in the region and as of April 2016, eight biosimilars have been approved in Japan and also due to their increasing applications in rheumatoid arthritis.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry